Kohji Miyazaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kohji Miyazaki has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Atsuko Katagiri
Department of Obstetrics and Gynecology, Shimane University School of Medicine
1 shared publication - Hiroshi Katagiri
Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane 6938501, Japan
1 shared publication - Kentaro Nakayama
Department of Obstetrics and Gynecology, East Medical Center, Nagoya City University, Nagoya 464-8547, Japan
1 shared publication - Kouji Iida
Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo 693-8501, Japan
1 shared publication - Masako Ishikawa
Department of Obstetrics and Gynecology, Shimane University School of Medicine, Enyacho 89-1, Izumo 6938501, Japan
1 shared publication - Mohammed Tanjimur Rahman
Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane 6938501, Japan
1 shared publication
Latest Publications
- Open Access
- 15 March 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (3) , 6067-6073
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies
Ovarian cancer treatment presently does not reflect molecular differences in histologic subtype. Ovarian clear cell carcinoma (OCCC) exhibits several differences in terms of molecular pathogenesis and tumor behavior from the more common, chemosensitive, serous carcinomas, which makes OCCC a candidate for targeted therapies. A 53-year-old Japanese woman was diagnosed with stage IIIc ovarian clear cell adenocarcinoma with marked chemoresistance to conventional regimens. She demonstrated a partial response to a multikinase inhibitor. The tumor was resistant to PI3K/mTOR pathway inhibitors despite harboring a PIK3CA mutation. The present case suggests a role for targeted therapies in the treatment of OCCC and a need for the identification of biomarkers that will predict response to targeted therapies.
- 15 March 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (3) , 6067-6073
Open AccessA Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies
Ovarian cancer treatment presently does not reflect molecular differences in histologic subtype. Ovarian clear cell carcinoma (OCCC) exhibits several differences in terms of molecular pathogenesis and tumor behavior from the more common, chemosensitive, serous carcinomas, which makes OCCC a candidate for targeted therapies. A 53-year-old Japanese woman was diagnosed with stage IIIc ovarian clear cell adenocarcinoma with marked chemoresistance to conventional regimens. She demonstrated a partial response to a multikinase inhibitor. The tumor was resistant to PI3K/mTOR pathway inhibitors despite harboring a PIK3CA mutation. The present case suggests a role for targeted therapies in the treatment of OCCC and a need for the identification of biomarkers that will predict response to targeted therapies.